Advances in Anesthesia for Shoulder Surgery: A Comprehensive ...
rct clinical trial :: Article Creator 'Breakthrough' CRISPR Treatment Slashes Cholesterol In First Human Clinical Trial CRISPR-based therapies just hit another milestone. In a small clinical trial with 10 people genetically prone to dangerously high levels of cholesterol, a single infusion of the precision gene editor slashed the artery-clogging fat by up to 55 percent. If all goes well, the one-shot treatment could last a lifetime. The trial, led by Verve Therapeutics, is the first to explore CRISPR for a chronic disease that's usually managed with decades of daily pills. It also marks the first use of a newer class of gene editors directly in humans. Called base editing, the technology is more precise—and potentially safer—than the original set of CRISPR tools. The new treatment, VERVE-101, uses a base editor to disable a gene encoding a liver protein that regulates cholesterol. To be clear, these results are just a sneak peek in...